Beletsky Leo, Ruthazer Robin, Macalino Grace E, Rich Josiah D, Tan Litjen, Burris Scott
Temple University Beasley School of Law, Philadelphia, PA 19122, USA.
J Urban Health. 2007 Jan;84(1):126-36. doi: 10.1007/s11524-006-9120-z.
Naloxone, the standard treatment for heroin overdose, is a safe and effective prescription drug commonly administered by emergency room physicians or first responders acting under standing orders of physicians. High rates of overdose deaths and widely accepted evidence that witnesses of heroin overdose are often unwilling or unable to call 9-1-1 has led to interventions in several US cities and abroad in which drug users are instructed in overdose rescue techniques and provided a "take-home" dose of naloxone. Under current Food and Drug Administration (FDA) regulations, such interventions require physician involvement. As part of a larger study to evaluate the knowledge and attitudes of doctors towards providing drug treatment and harm reduction services to injection drug users (IDUs), we investigated physician knowledge and willingness to prescribe naloxone. Less than one in four of the respondents in our sample reported having heard of naloxone prescription as an intervention to prevent opiate overdose, and the majority reported that they would never consider prescribing the agent and explaining its application to a patient. Factors predicting a favorable attitude towards prescribing naloxone included fewer negative perceptions of IDUs, assigning less importance to peer and community pressure not to treat IDUs, and increased confidence in ability to provide meaningful treatment to IDUs. Our data suggest that steps to promote naloxone distribution programs should include physician education about evidence-based harm minimization schemes, broader support for such initiatives by professional organizations, and policy reform to alleviate medicolegal concerns associated with naloxone prescription. FDA re-classification of naloxone for over-the-counter sales and promotion of nasal-delivery mechanism for this agent should be explored.
纳洛酮是治疗海洛因过量的标准药物,是一种安全有效的处方药,通常由急诊室医生或根据医生长期医嘱行事的急救人员给药。海洛因过量致死率居高不下,且有广泛认可的证据表明,海洛因过量的目击者往往不愿或无法拨打911,这促使美国和其他国家的几个城市采取干预措施,指导吸毒者掌握过量急救技术,并提供一剂“可带回家的”纳洛酮。根据美国食品药品监督管理局(FDA)目前的规定,此类干预措施需要医生参与。作为一项更大规模研究的一部分,该研究旨在评估医生对为注射吸毒者(IDU)提供药物治疗和减少伤害服务的知识和态度,我们调查了医生对开具纳洛酮处方的知识和意愿。在我们样本中的受访者中,不到四分之一的人表示听说过将纳洛酮处方作为预防阿片类药物过量的一种干预措施,大多数人表示他们永远不会考虑为患者开具这种药物并解释其用法。预测对开具纳洛酮持积极态度的因素包括对注射吸毒者的负面看法较少、不太重视来自同行和社区不治疗注射吸毒者的压力,以及对为注射吸毒者提供有效治疗的能力更有信心。我们的数据表明,促进纳洛酮分发项目的措施应包括对医生进行基于证据的伤害最小化方案的教育、专业组织对此类举措提供更广泛的支持,以及进行政策改革以减轻与纳洛酮处方相关的法医学担忧。应探索FDA将纳洛酮重新分类为非处方药销售以及推广该药物的鼻腔给药机制。